Evidence map›Paper›PMID 38917401›Full record

Trial reportJCO oncology practice2024

Leveraging Mobile Health to Improve Capecitabine Adherence Among Women With Breast Cancer: A Pilot Randomized Controlled Trial.

Ilana Graetz, Samuel Hernandez, Sara Arshad, Kristina Byers, Jane Meisel, Gelareh Sadigh, Elizabeth A Sakach, Keerthi Gogineni, Mylin A Torres

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ilana GraetzDepartment of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.ORCID 0000-0003-3664-5815
Samuel HernandezDepartment of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.
Sara ArshadDepartment of Health Policy and Management, Emory Rollins School of Public Health, Atlanta, GA.
Kristina ByersNovartis Pharmaceutical Corporation, Atlanta, GA.ORCID 0009-0001-8519-6465
Jane MeiselDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
Gelareh SadighDepartment of Radiological Sciences, University of California Irvine, Orange, CA.ORCID 0000-0003-3233-1878
Elizabeth A SakachDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.
Keerthi GogineniDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0002-9822-797X
Mylin A TorresDepartment of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-3582-5216

Funding

NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

purposeOral capecitabine improves convenience compared to intravenous therapies but presents monitoring challenges. We conducted a randomized pilot trial to evaluate a mobile health intervention to remotely monitor capecitabine adherence and patient-reported outcomes (PROs) among women with breast cancer.

methodsPatients with breast cancer prescribed capecitabine, an oral chemotherapy with a complex, cyclical regimen, were randomly assigned to enhanced usual care (EUC) or PRO arm. Participants were asked to use a smart pill bottle to measure adherence (timing and dose) and complete baseline and 90-day follow-up surveys. PRO participants received text messages for missed or incorrect doses and weekly text-based symptom assessments, and their oncologists received alerts for severe symptoms or missed doses. We compared nonadherence (<80%) and changes from enrollment to follow-up on reported physical and mental health quality-of-life scores and number of severe symptoms by study arm.

resultsOverall, 32 women were randomly assigned (17 EUC and 15 PRO): 28 (87.5%) received the intervention and 24 (78.1%) completed the follow-up survey. Among participants who received the intervention, PRO participants responded to 83.3% of symptom questions; 7.7% of PRO participants were nonadherent compared with 40.0% of EUC participants (

conclusionA mobile health intervention using text message reminders and symptom assessments improved medication adherence and mental health quality-of-life scores and lowered symptom burden of patients with breast cancer prescribed capecitabine. Future work should evaluate the longer-term impacts of this intervention.

Indexed as

Breast NeoplasmsCapecitabineMedication AdherenceTelemedicineAdultAgedAntimetabolites, AntineoplasticFemaleHumansMiddle AgedPilot ProjectsQuality of LifeText MessagingAntimetabolites, AntineoplasticCapecitabine

Identifiers

PMID38917401
PMCPMC12314880

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.